Estimated Cancer Prevalence by Cancer Site and Gender, New York City, 2019
Source: New York State Cancer Registry
Site of Cancer | Diagnosed in Last 5 Years | Ever Diagnosed | ||||
---|---|---|---|---|---|---|
Males and Females | Males | Females | Males and Females | Males | Females | |
All Invasive Malignant Tumors | 144,900 | 67,500 | 77,300 | 429,100 | 192,100 | 237,000 |
Oral cavity and pharynx | 3,300 | 2,100 | 1,200 | 9,300 | 5,700 | 3,600 |
Esophagus | 600 | 400 | 200 | 1,300 | 900 | 500 |
Stomach | 2,700 | 1,500 | 1,200 | 7,000 | 3,900 | 3,200 |
Colorectal | 12,100 | 6,200 | 5,900 | 38,300 | 18,100 | 20,200 |
Liver / intrahepatic bile duct | 2,300 | 1,600 | 700 | 4,500 | 3,100 | 1,400 |
Pancreas | 1,800 | 900 | 1,000 | 3,200 | 1,500 | 1,700 |
Larynx | 900 | 700 | 200 | 3,200 | 2,400 | 700 |
Lung and bronchus | 10,000 | 4,500 | 5,500 | 19,200 | 8,700 | 10,500 |
Melanoma of the skin | 4,000 | 2,100 | 1,800 | 13,600 | 6,700 | 6,900 |
Female breast | 27,700 | 91,800 | ||||
Cervix uteri | 1,600 | 9,400 | ||||
Corpus uterus and NOS | 6,600 | |||||
Ovary | 1,900 | 6,900 | ||||
Prostate | 24,500 | 81,800 | ||||
Testis | 1,000 | 5,200 | ||||
Urinary bladder (incl. in situ) | 5,900 | 4,400 | 1,500 | 16,400 | 11,900 | 4,500 |
Kidney and renal pelvis | 5,400 | 3,400 | 2,000 | 15,200 | 9,300 | 5,900 |
Brain and other central nervous system | 1,400 | 800 | 600 | 5,400 | 2,800 | 2,600 |
Thyroid | 8,900 | 2,100 | 6,800 | 28,000 | 6,000 | 22,000 |
Hodgkin lymphoma | 1,200 | 600 | 600 | 6,100 | 3,100 | 3,000 |
Non-Hodgkin lymphomas | 6,900 | 3,500 | 3,300 | 20,300 | 10,300 | 10,000 |
Myeloma | 3,100 | 1,600 | 1,500 | 5,900 | 2,900 | 3,000 |
Leukemias | 4,300 | 2,400 | 1,900 | 11,800 | 6,500 | 5,400 |
Notes
- Estimated number of residents alive as of January 1, 2019, diagnosed with cancer within the last 5 years or anytime in the past, respectively.
- Numbers are rounded to the nearest 100.
- Refer to https://www.naaccr.org/wp-content/uploads/2020/01/CINA12-16.v5.sec1_.pdf for a detailed description of prevalence methodology.